Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Famitinib by Jiangsu Hengrui Medicine for Follicular Thyroid Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Follicular Thyroid Cancer. According to...
Famitinib by Jiangsu Hengrui Medicine for Renal Cell Carcinoma: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Renal Cell Carcinoma. According to...
Famitinib by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Cervical Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Cervical Cancer. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Anaplastic Thyroid Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Anaplastic Thyroid Cancer. According to...
Famitinib by Jiangsu Hengrui Medicine for Thyroid Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Thyroid Cancer. According to GlobalData,...
Famitinib by Jiangsu Hengrui Medicine for Medullary Thyroid Cancer: Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Medullary Thyroid Cancer. According to...
Famitinib by Jiangsu Hengrui Medicine for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
Famitinib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Triple-Negative Breast Cancer (TNBC). According...